GT
BSTG

Glenmede Trust’s Biostage, Inc. Common Stock BSTG Stock Holding History

Glenmede Trust’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,000
Closed -$2K – 2852
2015
Q3 		$2K Hold
3,000
– – ﹤0.01% 2548
2015
Q2 		$4K Hold
3,000
– – ﹤0.01% 2320
2015
Q1 		$9K Buy
+3,000
New +$10.2K ﹤0.01% 2155

Other funds holding BSTG

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSP
Tappan Street Partners Chicago, Illinois $35.7M AUM 42.68% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Trust's BSTG Position: Q4 2015 in Review

Glenmede Trust sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2015, closing a stake of 3,000 shares — an estimated $2K sold.

Glenmede Trust first reported a position in BSTG in Q1 2015 and held it in 3 quarters. The position peaked at $9K in Q1 2015. 28 funds tracked by Wall St. Rank hold BSTG as of Q4 2015.

  • Glenmede Trust reported no remaining Biostage, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Glenmede Trust sold 3,000 Biostage, Inc. Common Stock shares in Q4 2015, an estimated $2K.
  • Glenmede Trust first reported a position in Biostage, Inc. Common Stock in Q1 2015 and held it in 3 quarters.
  • Glenmede Trust's Biostage, Inc. Common Stock position peaked at $9K in Q1 2015.
  • 28 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.